AMGN
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FAMGN.O%2Fkey-developments%2Farticle%2F2507350&ei=oIaaUtD9BYSQ0QGK1wE&usg=AFQjCNF7e3EGchwb-CPKjV3eVg8QJML-IA
Amgen, Inc. Announces Positive Results From Phase 1b Clinical Study Of AMG 145
Sunday, 25 Mar 2012 11:45am EDT
Amgen, Inc. announced positive results from a Phase 1b clinical study of AMG 145, an investigational PCSK9 inhibitor, in patients with high cholesterol who were taking statins. The study demonstrated that multiple doses of AMG 145 significantly reduced serum low density lipoprotein cholesterol (LDL-C), also known as 'bad' cholesterol, by up to 81% versus placebo (maximum reduction) in subjects on low to moderate doses of statins (p
